AcelRx Makes Headway With Second Pain Drug-Device Combo
This article was originally published in Scrip
Executive Summary
With its lead drug candidate Zalviso in US FDA limbo, AcelRx Pharmaceuticals is focused on its other late-stage pain drug ARX-04, a health care professional-administered sublingual tablet that delivered fast relief of moderate-to-severe post-surgical pain for patients enrolled in a Phase III clinical trial.
You may also be interested in...
Pain In The (ER) Battlefield: AcelRx Reports Positive ARX-04 Results
AcelRx reports fast-acting, pain-reducing data for ARX-04 in emergency room-treated trauma patients, which is the setting that most closely resembles battlefield situations experienced by personnel in the US military – the Phase III program's co-funder.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.